NK cell effector functions are powerfully unleashed through CD16 engagement by IgG-coated tumor cells; thus, much interest fuels novel developments aimed at potentiating this tool in order to improve tumor-targeting mAb therapeutic efficacy. This evidence concerns the gene FCGR3A and neoplasm.